{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03042221",
            "orgStudyIdInfo": {
                "id": "15-2316.cc"
            },
            "organization": {
                "fullName": "University of Colorado, Denver",
                "class": "OTHER"
            },
            "briefTitle": "Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",
            "officialTitle": "Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "early-rebiopsy-to-identify-biomarkers-of-tumor-cell-survival-following-egfr-alk-or-braf-tki-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-05-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-01-30",
            "studyFirstSubmitQcDate": "2017-02-01",
            "studyFirstPostDateStruct": {
                "date": "2017-02-03",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-01-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Colorado, Denver",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
                "Non-Small Cell Lung Cancer",
                "EGFR Gene Mutation",
                "ALK Gene Mutation",
                "ROSE Cluster 1",
                "BRAF V600E"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "OTHER"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITHOUT_DNA",
                "description": "Tumor tissue"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "gene expression changes",
                    "description": "change from baseline of tumor gene expression profile at 2 weeks. Global gene expression data will be collected using RNAseq",
                    "timeFrame": "baseline and 2 weeks (+/- 1 week) for each patient."
                },
                {
                    "measure": "protein expression change",
                    "description": "change from baseline of protein gene expression profile at 2 weeks as measured by multiplex protein assay (proteins to be assayed include: e-cadherin, vimentin, fibronectin, CD4, CD8, CD14, CD16, CD206, PDL1, and CSF1R)",
                    "timeFrame": "baseline and 2 weeks (+/- 1 week) for each patient."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Depth of Response",
                    "description": "Correlation between the depths of tumor response (by RECIST v1.1) (percentage decrease in tumor size) with the presence of an EMT signature.",
                    "timeFrame": "Study startup through 36 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Evaluation of Adverse Events",
                    "description": "Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0",
                    "timeFrame": "Study startup through 36 months"
                },
                {
                    "measure": "Success rate of Repeat Biopsy",
                    "description": "Success rate of early rebiopsy in obtaining tumor samples that have evaluable material for RNA Seq and other analyses",
                    "timeFrame": "Study startup through 36 months"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "Length of PFS as per RECIST 1.1",
                    "timeFrame": "Study startup through 36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nTargetable Oncogene - Biopsy Cohort (includes blood draw)\n\n1. Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapies (per current NCCN guidelines)\n2. Aged 18 years or older\n3. ECOG 0-2\n4. Have a histologically confirmed diagnosis of NSCLC harboring an activating mutation responsive to targeted therapy (per NCCN guidelines)\n5. No prior systemic therapy for locally advanced or metastatic disease.\n6. Planned treatment with targeted therapy specific to the oncogene driver mutation.\n7. Patients must have at least one site of measurable disease \u2265 2cm.\n8. Primary disease site or site of metastatic disease must be amenable to biopsy.\n9. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nTargetable Oncogene - Blood Draw Only Cohort\n\n1. Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapy (per NCCN guidelines)\n2. Aged 18 years or older\n3. ECOG 0-2\n4. Have a histologically confirmed diagnosis of NSCLC harboring an activating mutation responsive to targeted therapy (per NCCN guidelines)\n5. No prior systemic therapy or radiotherapy for metastatic lung cancer (surgery alone permitted)\n6. Planned treatment with targeted therapy specific to the oncogene driver mutation.\n7. Declines repeat biopsy option or does not have tumor site amenable to biopsy.\n8. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nImmunotherapy Cohort - Blood Draw Only\n\n1. Have a histologically confirmed diagnosis of locally advanced or stage IV NSCLC without a treatable activating mutation that would be amenable to targeted therapy AND planned first line treatment with immunotherapy or chemotherapy plus immunotherapy.\n2. Aged 18 years or older\n3. ECOG 0-2\n4. No prior systemic therapy or radiation therapy for lung cancer (surgery alone permitted)\n5. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nExclusion Criteria:\n\nTargetable Oncogene - Biopsy Cohort (includes blood draw)\n\n1. Concurrent health problem which would preclude tissue biopsy (e.g. hemophilia or other bleeding predisposition).\n2. Patients whose only biopsy source would involve sampling an anatomic area that carries an unacceptably high procedural risk (e.g. pericardium or kidney) as deemed by the treating physician or by a proceduralist performing the biopsy.\n3. Patients whose only biopsy source involves a sample that may not be evaluable due to insufficient genomic material (such as cerebrospinal or ascitic fluid) as deemed by the treating physician. .\n\nTargetable Oncogene Cohort and Immunotherapy Cohort - Blood Draw Only\n\n1. Planned follow up on therapy outside of the University of Colorado Health System\n2. Unwillingness to allow for residual clinical biopsy specimens to be utilized in this study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Subjects who have a diagnosis of State IV Lung Adenocarcinoma with EGFR activating mutation",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brandi Kubala",
                    "role": "CONTACT",
                    "phone": "303-724-1657",
                    "email": "brandi.kubala@cuanschutz.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Erin Schenk",
                    "affiliation": "University of Colorado, Denver",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Colorado, Cancer Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brandi Kubala",
                            "role": "CONTACT",
                            "phone": "303-724-1657",
                            "email": "brandi.kubala@cuanschutz.edu"
                        },
                        {
                            "name": "Erin Schenk",
                            "role": "CONTACT",
                            "phone": "303-724-4304",
                            "email": "erin.schenk@cuanschutz.edu"
                        },
                        {
                            "name": "Erin Schenk",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-Small Cell Carcinoma of Lung",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}